Evidence map›Paper›PMID 41527433›Full record

ReviewMolecular oncology2026

Targeting p38α in cancer: challenges, opportunities, and emerging strategies.

Angel R Nebreda

Abstract readReview
In one paragraph

Review in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Angel R NebredaInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Spain.ORCID 0000-0002-7631-4060

Funding

Asociación Española Contra el Cancer PROYE18035RODRCatalan Agency for Management of University and Research Grants 2021 SGR-909Fundació D'Estudis i Recerca Oncològica BFERO2025.02Ministerio de Ciencia e Innovación, Spain PID2022-136646OB-I00Ministerio de Ciencia e Innovación, Spain PLEC2022-009227
6 · The paper itself

Abstract

The protein kinase p38α is an important regulator of cell homeostasis that has been implicated in the response to many types of stresses. Given the plethora of functions that can be potentially regulated by p38α, this pathway has been linked to many diseases including cancer, suggesting a potential therapeutic interest in targeting p38α. This Viewpoint focuses on the role of p38α stress signaling in cancer development and therapy, discussing recent reports and reflecting on future challenges.

Indexed as

Mitogen-Activated Protein Kinase 14Molecular Targeted TherapyNeoplasmsAnimalsHumansSignal TransductionMitogen-Activated Protein Kinase 14cancer cell viabilitycancer therapycontext‐dependent signalingp38α (MAPK14)tumor microenvironment

Identifiers

PMID41527433
PMCPMC13060641

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.